Clinical Trials
17 trialsNCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT06695845 2026-04-09
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Phase 2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT06632262 2024-11-19
A Phase 2 Clinical Study of ABSK061 and ABSK043
Abbisko Therapeutics Co, Ltd
Phase 2 Recruiting
NCT05229614 2024-08-21
ICONIC
CNAO National Center of Oncological Hadrontherapy
Phase 2 Recruiting
NCT06551896 2024-08-13
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03735680 2023-07-07
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine, Inc.
Phase 2 Completed
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT04125693 2022-04-01
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
Phase 2 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown